Blys upregulation in Sjö gren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands

Rheumatology (United Kingdom)

Volumn 52, Issue 2, 2013, Pages 276-281

  Quartuccio, Luca ^a   Salvin, Sara ^a   Fabris, Martina ^b   Maset, Marta ^a   Pontarini, Elena ^a   Isola, Miriam ^a   De Vita, Salvatore ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

B cell activating factor; Blys; Lymphoma; S; Salivary glands

Indexed keywords

B CELL ACTIVATING FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL CLONAL EXPANSION; CELL EXPANSION; CHILD; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE ACTIVITY; DISEASE ASSOCIATION; EUROPEAN LEAGUE AGAINST RHEUMATISM SS DISEASE ACTIVITY INDEX; FEMALE; HEPATITIS C VIRUS; HUMAN; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PAROTID GLAND DISEASE; PAROTID SWELLING; PRIORITY JOURNAL; SALIVARY GLAND; SALIVARY GLAND BIOPSY; SCHOOL CHILD; SEROLOGY; SJOEGREN SYNDROME; UPREGULATION; VASCULITIS;

EID: 84875684077     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes180     Document Type: Article

References (28)

1. Tzioufas AG, Katsikis PD, Youinou PY, Moutsopoulos HM. Sjögren's syndrome: an oligo-monoclonal B cells process. Clin Exp Rheumatol 1990;8(Suppl 5):17-21.
2. Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjö gren's syndrome: clinical and pathophysiologic aspects. Medicine 2009;88: 284-93.
3. Theander E, Vasaitis L, Baecklund E et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011;70: 1363-68.
4. De Vita S, Ferraccioli GF, De Re V et al. Polymerase chain reaction to assess B-cell clonality in clinical conditions at risk for B-cell malignancy. Transplant Proc 1994;26: 3229-32.
5. Mariette X, Roux S, Zhang J et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjö gren's syndrome. Ann Rheum Dis 2003;62:168-171.
6. Groom J, Kalled SL, Cutler AH et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjö gren's syndrome. J Clin Invest 2002;109:59-68.
7. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjö gren's syndrome. J Clin Immunol 2005;25:189-201.
8. Lavie F, Miceli-Richard C, Quillard J et al. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjö gren's syndrome. J Pathol 2004;202: 496-502.
9. Seror R, Ravaud P, Bowman SJ et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjö gren's syndrome. Ann Rheum Dis 2010;69:1103-9.
10. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjö gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
11. De Vita S, Soldano F, Isola M et al. Preliminary classification criteria for the cryoglobulinemic vasculitis. Ann Rheum Dis 2011;70:1183-90.
12. Fabris M, Quartuccio L, Sacco S et al. B-lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinemia syndrome and hepatitis-C virus infection. Rheumatology 2007;46:37-43.
13. Beer RG, Rischmueller M, Coates T et al. Nonprecipitating anti-La(SS-B) autoantibodies in primary Sjö gren's syndrome. Clin Immunol Immunopathol 1996;79:314-8.
14. Quartuccio L, Fabris M, Salvin S et al. Bone marrow B-cell clonal expansion in type II mixed cryoglobulinaemia: association with nephritis. Rheumatology 2007;46: 1657-61.
15. Ekström Smedby K, Vajdic CM, Falster M et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008;111:4029-38.
16. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002;2:465-75.
17. Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005;8:243-65.
18. Batten M, Fletcher C, Ng LG et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004;172:812-22.
19. Szodoray P, Alex P, Jonsson MV et al. Distinct profiles of Sjö gren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 2005;117:168-76.
20. Daridon C, Devauchelle V, Hutin P et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjö gren's syndrome. Arthritis Rheum 2007;56:1134-44.
21. Novak AJ, Grote DM, Stenson M et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004;104:2247-53.
22. Pertovaara M, Korpela M. Serum b2 microglobulin correlates with the new ESSDAI in patients with Sjö gren's syndrome. Ann Rheum Dis 2011;12:2236-7.
23. De Vita S, Quartuccio L, Salvin S et al. Cryoglobulinaemia related to Sjögren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. Rheumatology 2012;51:627-33.
24. De Vita S, Quartuccio L, Isola M et al. A randomized, controlled, trial of rituximab for treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:843-53.
25. Meijer JM, Meiners PM, Vissink A et al. Effectiveness of rituximab treatment in primary Sjö gren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
26. Ramos-Casals M, la Civita L, De Vita S et al. Characterization of B cell lymphoma in patients with Sjö gren's syndrome and hepatitis C virus infection. Arthritis Rheum 2007;57:161-70.
27. Pers JO, Devauchelle V, Daridon C et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjö gren's syndrome. Arthritis Rheum 2007;56:1464-77.
28. Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005;174:817-26.